TrialOral oncology2012
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Missak Haigentz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this papercites it